Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis
Authors' conclusion
Together, the enterotype-based gut microbial human index (EGMI) classifier was useful to precisely and effectively identify enterotypes of individual RA patients, which could effectively evaluate MTX clinical responses.
Study context
- Population
- Rheumatoid arthritis (RA) patients; validation cohort in Shanghai, China, and another independent RA cohort for methotrexate (MTX) responseplus cohorts of 66 and 27
- Participants
- 145 patients
- Exposure
- Enterotype RA E1 vs RA E2
- Outcome
- Whether gut microbiota patterns (enterotypes) predict MTX efficacy in RA
Methodological details16S rRNA gene sequencing, Dirichlet multinomial mixture clustering, validation cohort, independent cohort
- 16S rRNA gene sequencing
- Dirichlet multinomial mixture clustering
- Validation cohort
- Independent cohort
Main finding
As reported in the abstract
- RA patients displayed two dysbiotic patterns: RA E1 (predominantly Prevotella) and RA E2 (predominantly Bacteroides)
- Significant associations of RA E1 with clinical response to subsequent MTX, confirmed in an independent RA cohort
Observational data: associations, not effects.
Further findings
Lymphocyte subsets and cytokines
- Only the number of CD8+ T cells differed significantly between RA E1 and RA E2; validated in the Shanghai cohort
Original publication
Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). Published 10 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →